8,241 Shares in Natera, Inc. $NTRA Acquired by Keebeck Wealth Management

Keebeck Wealth Management bought a new position in Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,241 shares of the medical research company’s stock, valued at approximately $2,237,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in NTRA. Keating Financial Advisory Services Inc. acquired a new position in shares of Natera during the 2nd quarter valued at $58,000. Encore Global Management LP acquired a new stake in shares of Natera in the second quarter valued at $1,629,000. Allworth Financial LP acquired a new stake in shares of Natera in the second quarter valued at $1,053,000. B. Metzler seel. Sohn & Co. AG bought a new position in Natera during the second quarter valued at about $840,000. Finally, Virtus Advisers LLC bought a new position in Natera during the second quarter valued at about $1,015,000. 99.90% of the stock is owned by institutional investors.

Insider Transactions at Natera

In other Natera news, insider Solomon Moshkevich sold 3,410 shares of Natera stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $265.58, for a total transaction of $905,627.80. Following the transaction, the insider directly owned 129,019 shares in the company, valued at approximately $34,264,866.02. The trade was a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director directly owned 4,250 shares in the company, valued at approximately $1,062,500. This trade represents a 79.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 181,045 shares of company stock worth $41,330,968. 5.05% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on NTRA. Wall Street Zen cut shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. BTIG Research lifted their price objective on shares of Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 target price for the company. Evercore restated an “outperform” rating and set a $300.00 target price on shares of Natera in a report on Monday, July 6th. Finally, Sanford C. Bernstein started coverage on shares of Natera in a research report on Friday, June 26th. They issued an “outperform” rating and a $310.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $319.38.

Natera Trading Up 2.2%

NTRA stock opened at $332.03 on Friday. Natera, Inc. has a one year low of $157.43 and a one year high of $333.56. The firm has a 50-day moving average of $274.24 and a two-hundred day moving average of $229.39. The firm has a market capitalization of $47.86 billion, a PE ratio of -244.14 and a beta of 1.51.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period last year, the firm posted ($0.74) earnings per share. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. On average, equities research analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.